Final Results of the Novel Healing-Targeted DES With Synchronized Antiproliferative Drug Delivery to Target Smooth Muscle Cell Proliferation After DES Implantation in Coronary Artery Disease: 5-Year Results of the PIONEER III Trial

Within the prior 24 months, I have had a financial relationship with a company producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients:

• Consultant Fee/Honoraria/Speaker's Bureau - Boston Scientific Corporation; Abiomed; Cordis / MedAlliance
• Grant Support/Research Contract - Abbott; Sinomed; Abiomed